Navigation Links
Pregis Announces Fourth Quarter and Full Year 2008 Financial Results
Date:3/26/2009

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify forward-looking statements by the Company's use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "seek," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. For a discussion of key risk factors, please see the risk factors disclosed in the Company's filings with the Securities & Exchange Commission, including the Company's annual report on Form 10-K and quarterly reports on Form 10-Q. These risks may cause actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Given these risk and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. The Company undertakes no duty to update its forward-looking statements.


                           Pregis Holding II Corporation
                            Consolidated Balance Sheets
                                    Unaudited
               (dollars in thousands, except shares and per share data)

                                                           December 31,
                                                           ------------
                                                          2008      2007
                                                          ----      ----
    Assets
   
'/>"/>
SOURCE Pregis Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Pregis Announces Investor Conference Call to Review Fourth Quarter and Full Year 2008 Financial Results
2. Pregis Announces Third Quarter 2008 Financial Results
3. Pregis Announces Investor Conference Call to Review 2008 Third Quarter Financial Results
4. Pregis Announces Second Quarter 2008 Financial Results
5. Pregis Announces First Quarter 2008 Financial Results
6. Pregis Announces Fouth Quarter and Full Year 2007 Financial Results
7. Pregis Announces Investor Conference Call to Review 2007 Fourth Quarter and Full Year Financial Results
8. Pregis Corporation Appoints New President of Protective Packaging North America
9. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
10. Sagent Pharmaceuticals Announces U.S. FDA Approval of Azithromycin for Injection
11. Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... (PRWEB) July 28, 2014 Cuidado Casero ... and hospice, PCO, PCA, and PHC in Texas, New Mexico, ... a sponsor of the North Texas Chapter of PAM’s 2014 ... the Peruvian American Medical Society. The North Texas chapter was ... and other professionals interested in improving medical care for the ...
(Date:7/27/2014)... 2014 Hyaluronic Acid can hold 1,000 ... key to the power of Hyaluronic Serums. , "Hyaluronic ... founder of Sublime Beauty®. "But like collagen, it diminishes ... ours improves skin moisture-retention and radiance." , Hyaluronic ... a healthy and beautiful look. Key Ingredients in the ...
(Date:7/27/2014)... Detroit, MI (PRWEB) July 27, 2014 ... the public with organic ways to achieve a younger ... eye cream buyer's guide to help men and women ... . , The details that are presented in the ... range of price information for consumers. On drawback to ...
(Date:7/27/2014)... new pill-only antiviral drug regimens could provide shorter, more ... majority of patients infected with hepatitis C, even those ... two studies published in The Lancet . , ... is the most common genotype in the USA, Europe, ... the most difficult to treat. , Around 150 million ...
(Date:7/27/2014)... a powerful drug given at the time of a ... of rejection, but that it also allows a less ... the operation. , The key results are reported in ... Transplant Congress in San Francisco today. They will help ... combinations of treatments used to prevent early kidney rejection ...
Breaking Medicine News(10 mins):Health News:Cuidado Casero Sponsors Peruvian American Medical Society (PAMS) Gala 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 3Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 3
... cause damage to the brain of youngsters, says a ... misuse can do to them. // ,Thomas Heffernan, ... students for the research presented at the British Psychological ... of Daily Mail. ,Half the students ...
... research team from the New York University College of Dentistry ... oral decay evolved along with its human hosts. ... common ancestor who lived in Africa between 100,000 and 200,000 ... by Page Caufield, a professor of cariology and comprehensive care ...
... in EMBO says that the parasite that is responsible ... new pathway. Sleeping sickness is caused by Trypanosoma brucei ... ,Shulamit Michaeli and colleagues describe a pathway in T. ... this pathway shuts down the synthesis of a crucial ...
... the healthcare sector with a super-specialty hospital in Gurgaon,// on ... of Rs.2.1 billion ($45 million). ,Christened Artemis Health ... will open next month. "In the second phase, another 240 ... of AHS. ,"This is the first of similar ...
... governments to join the anti-tuberculosis global plan, which would ... disease has become extremely drug-resistant. ,Ban's message ... on Saturday. The World Health Organization (WHO) recently reported ... of tuberculosis, XDR-TB, which threatens to derail efforts to ...
... be hampered if they indulge in excessive drinking.// This ... a psychologist from Northumbria University. ,Alcohol and ... young age which could extend into adulthood. According to ... a very crucial stage. ,Dr. Thomas Heffernan ...
Cached Medicine News:Health News:Tooth Decay Bacteria Evolved Along With Man 2
(Date:7/28/2014)... Germany and LONDON , ... , Collaboration aims to create and commercialize companion diagnostic ... use of IRESSA  for non-small cell lung cancer patients  ... FDA-approved  therascreen   EGFR test and is planned to run on Rotor-Gene ... Project enabled by AstraZeneca master framework agreement ...
(Date:7/25/2014)... July 25, 2014  In today,s marketplace, launching multiple ... challenging - as is managing a portfolio of products ... it possible - or even preferable - to pool ... can you combine resources and activities, and what marketing ... These are just a few of the dilemmas facing ...
(Date:7/25/2014)... 25, 2014 /PRNewswire-iReach/ -- Full Service CRO ... new Vice President of Business Development. Peter has been ... a number of different business development positions with some ... were primarily related to business development/sales management and marketing.  ... years makes him a key and strategic asset to ...
Breaking Medicine Technology:QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2
... FALLS, N.J., Dec. 22, 2010 Regenicin, Inc. (OTC Bulletin ... the development of regenerative cell therapies to restore the health ... Annual OneMedForum on January 11-13, 2011 in San Francisco. Randall ... and business model for bringing new regenerative medicine products to ...
... MiMedx Group, Inc. (OTC Bulletin Board: ... patent protected biomaterial-based products, announced today that it has ... leader in the development of tissue processing techniques for ... amnion membranes. Privately held Surgical Biologics was ...
Cached Medicine Technology:Regenicin CEO to Present at OneMedForum Business Development and Finance Conference 2MiMedx Announces Agreement to Acquire Surgical Biologics 2MiMedx Announces Agreement to Acquire Surgical Biologics 3MiMedx Announces Agreement to Acquire Surgical Biologics 4MiMedx Announces Agreement to Acquire Surgical Biologics 5
Small, removable blades, length 178 mm, (7"). Function: tissue retracting....
Toothed Pituitary Rongeurs, 12 300 mm....
Ferris Smith Rongeurs, 12 overall length 300 mm....
The Skull Pins are inserted into the receptacles of the Skull Clamp and fixate the head during surgery....
Medicine Products: